Status:
COMPLETED
A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in aHUS Patients in South Korea
Lead Sponsor:
Handok Inc.
Conditions:
aHUS
Eligibility:
All Genders
Brief Summary
Primary objective \- To determine the clinical prognosis by identifying the disease course and severity by treatment with or without eculizumab in patients with aHUS in Korea. Secondary objectives ...
Detailed Description
As a retrospective, non-interventional, multi-center study
Eligibility Criteria
Inclusion
- Patients who are clinically diagnosed with the aHUS
Exclusion
- Patients who are diagnosed with Shiga toxin-producing E. coli hemolytic-uremic syndrome (STEC-HUS).
- Patients with less than 10% in a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS-13) activity test
Key Trial Info
Start Date :
October 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT05405777
Start Date
October 4 2022
End Date
December 31 2022
Last Update
January 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Handok
Seoul, South Korea